Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings
AstraZeneca’s New Lupus Treatment Is Also Under Review
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
You may also be interested in...
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
Vifor Pharma has resubmitted a marketing application for avacopan to the European Medicines Agency – this time for an unconditional approval.
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.